


**AMENDMENTS TO THE SPECIFICATION:**

Kindly replace the paragraph beginning on page 5, line 9 with the following:

--The invention is therefore first directed to a novel use of beta-naphthoquinone derivatives for making drugs with an inhibitory effect on the extracellular glutamate release, wherein said derivatives are selected among the group consisting of:


(i) compounds having the formula (I):




(I)

wherein R represents -NH-CO-NH<sub>2</sub>, -NH-CO-CH<sub>3</sub>, or -OH group,

(ii) glucuronide derivatives thereof having the formula (II):



(II)




(iii) addition salts thereof.

Kindly replace the paragraph beginning on Page 7, line 28 and ending on Page 8, line 24, with the following:

Thus the present invention further relates to a method for treating and/or preventing glutamate-evoked cytotoxicity in a patient in need thereof comprising administering to said patient a composition containing a therapeutically effective amount of at least one beta-naphthoquinone derivative and a pharmaceutically acceptable carrier, wherein said derivative is selected among the group consisting of:


(i) compounds having the formula (I):




(I)

wherein R represents -NH-CO-NH<sub>2</sub>, -NH-CO-CH<sub>3</sub>, or -OH group, and

(ii) glucuronide derivatives thereof having the formula (II):



(II)



wherein R is as above indicated, and

(iii) addition salts thereof.